Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants.

Autor: Kumano O; Sysmex Corporation, Kobe, Japan.; Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Takamatsu, Japan., Suzuki S; Department of Cardiovascular Medicine, The Cardiovascular Institute, Tokyo, Japan., Yamazaki M; Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan.; Department of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan., An Y; Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.; Department of Cardiology, Saiseikai Noe Hospital, Osaka, Japan., Yasaka M; Department of Cerebrovascular Medicine and Neurology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.; Fukuoka Neurosurgical Hospital, Fukuoka, Japan., Ieko M; Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan. iekomno2020@gmail.com.; Department of Nursing, Sapporo University of Health Sciences, 1-15, Nakanuma Nishi-4-2, Higashi-ku, Sapporo, Hokkaido, 007-0894, Japan. iekomno2020@gmail.com.
Jazyk: angličtina
Zdroj: International journal of hematology [Int J Hematol] 2024 Apr; Vol. 119 (4), pp. 407-415. Date of Electronic Publication: 2024 Feb 09.
DOI: 10.1007/s12185-024-03712-4
Abstrakt: Age is a significant risk factor for ischemic stroke. However, the influence of aging on coagulation parameters in non-valvular atrial fibrillation (NVAF) patients treated with direct oral anticoagulants (DOACs) remains unclear. A total of 775 samples were collected from 224 NVAF patients receiving apixaban, edoxaban or rivaroxaban. The samples were categorized into three age groups: (i) ≤ 64 years, (ii) 65-74 years, and (iii) ≥ 75 years (apixaban: N = 48, 108, 119; edoxaban: N = 63, 68, 126; rivaroxaban: N = 115, 90, 38, respectively). Coagulation parameters including fibrinogen (Fbg), factor II, factor V, factor VII, factor X, and D-dimer, were compared between the three age groups for each drug. The slopes in the correlation between drug concentrations and modified diluted prothrombin time (mdPT) were also assessed. Fbg and factor V increased with age, while factor II and factor X decreased. Factor VII and D-dimer showed no significant differences across age categories. The slope in response to drug concentrations was similar between the age groups. In NVAF patients treated with apixaban, edoxaban and rivaroxaban, some coagulation parameters exhibited age-related variation. However, the response of mdPT to drug concentration was consistent across age categories.
(© 2024. Japanese Society of Hematology.)
Databáze: MEDLINE
Externí odkaz: